Key Points - SpaceX's application to launch 1 million satellites has been accepted by the FCC, aiming to create a data center network in orbit to support advanced AI models [4][5] - NIO has announced a profit forecast for Q4 2025, expecting an adjusted operating profit between RMB 700 million (approximately $100 million) and RMB 1.2 billion (approximately $172 million), marking its first quarterly profit [7][8] - The 2025 Hurun China 500 list shows TSMC retaining the top position with a value increase of RMB 3.5 trillion, while Xiaomi enters the top ten for the first time with a valuation of RMB 1 trillion [13][14] - Alibaba has unified its AI model branding under "Qwen" and launched a promotional campaign offering 3 billion RMB in discounts through its Qwen app [15][16] - Baidu plans to distribute dividends for the first time in 2026 and has authorized a share buyback program of up to $5 billion [16][17] - Li Auto is set to implement a "store partner" program to enhance operational efficiency and market responsiveness, giving store managers greater decision-making power [19] - Intel has appointed a new chief GPU architect, while Qualcomm has lost three key executives in a month [45][46] - Coupang has reported an expansion of a personal information leak affecting an additional 165,000 accounts, following a previous incident [53][54]

Core Viewpoint - Peijia Medical-B (09996) reported annual performance for the period ending December 31, 2025, with revenue approximately RMB 700 million to 720 million, reflecting a year-on-year growth of about 13.7% to 17.0% [1][3]. Group 1: Revenue Performance - The company achieved revenue of approximately RMB 700 million to 720 million during the reporting period [1][3]. - The year-on-year growth rate is estimated to be between 13.7% and 17.0% [1][3]. Group 2: Growth Drivers - The sustained revenue growth is primarily attributed to the strong performance of all three major product lines in the neurointerventional business [1][5]. - The market share in China's transcatheter aortic valve replacement (TAVR) sector continues to expand, driven mainly by the successful launch of the high-end TaurusMax® 3D adjustable TAVR system [1][5].

Core Viewpoint - The stock of Xinmai Medical (688016) has shown a slight increase, with a closing price of 99.25 yuan on February 5, 2026, reflecting a 1.66% rise, while the overall market sentiment indicates mixed capital flows with significant retail investor inflow [1][5]. Financial Performance - Xinmai Medical reported a total revenue of 1.015 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 4.66% [4]. - The net profit for the same period was 429 million yuan, showing a year-on-year decline of 22.46% [4]. - The gross profit margin stands at 70.4%, significantly higher than the industry average of 50.55% [4]. Market Position - Xinmai Medical's total market capitalization is 12.234 billion yuan, which is above the industry average of 11.126 billion yuan, ranking 27th out of 128 companies in the medical device sector [4]. - The company has a price-to-earnings (P/E) ratio of 21.38, which is considerably lower than the industry average of 93.58, ranking 13th in the industry [4]. Capital Flow Analysis - On February 5, 2026, the net outflow of main funds was 10.8214 million yuan, accounting for 4.87% of the total transaction amount, while retail investors saw a net inflow of 15.6052 million yuan, representing 7.02% of the total [1][2]. - Over the past five days, the stock has experienced fluctuating capital flows, with notable retail investor activity during periods of price increases [1][2]. Institutional Ratings - In the last 90 days, four institutions have issued buy ratings for Xinmai Medical, with an average target price of 122.06 yuan [5].

省药监局相关处室负责人介绍，为切实提高药品监管能力，陕西药品监管"一体化"运行机制全面建 立运行，药品监管党政同责有效落实，省、市、县食品药品安全委员会机制健全，监管机构职能清晰、 运行顺畅。 2月5日，记者从省药监局获悉："十四五"以来，陕西药品监管系统持续深化监管改革，药品安全风 险防控得到有效落实，截至2025年底，陕西药品、疫苗、医疗器械、化妆品监管实现全覆盖。 在推进药品智慧监管建设方面，陕西已建成药品监管综合业务系统、陕西省疫苗（药品）追溯监管 系统、陕西省药品监管大数据中心，实现省、市、县三级药械化监管业务"一网通办"，疫苗、特殊药 品、血液制品、集采中选产品等重点药品实现全链条信息可追溯。全省药品监管各类信息集成共享，风 险识别、风险预警、风险处置实现闭环管理。（记者：周明） 为支持"两品一械"（药品、化妆品、医疗器械）产业高质量发展，"十四五"以来，陕西药监系统持 续深化审评审批制度改革，药械化创新取得显著成效。I类创新药甲磺酸普雷福韦片获批上市，实现陕 西I类创新药零的突破。5个三类医疗器械创新产品获批上市。2种化妆品新原料通过国家药监局备案。 196个品种药品通过或视同通过仿制药一致性评 ...

Group 1 - The store involved in the incident with two middle school girls issued an apology and stated it would implement thorough reforms following the wrongful detention of the girls, who were suspected of shoplifting [1][5] - The incident occurred on February 2, when the girls were detained for 20-30 minutes after the store received a video alert from headquarters, leading to a confrontation with the girls' parents and police involvement [7] Group 2 - Meituan announced a $717 million acquisition of Dingdong Fresh, with the deal allowing Dingdong to withdraw up to $280 million from its group while ensuring a minimum net cash of $150 million [7] - Dingdong's founder emphasized that the company's core competitive advantages would remain intact post-merger, and the business and team would continue to operate stably [8] Group 3 - Xiaomi announced a reduction in the safety mileage threshold for its assisted driving feature from 1,000 km to 300 km to help users gradually familiarize themselves with the technology [11] - Tencent Games released a notification limiting gameplay for minors during the winter vacation period, allowing only 15 hours of playtime over 29 days [12] Group 4 - The China Securities Regulatory Commission initiated an investigation into the actual controller of Beiliqingsong, Ma Xuejun, for suspected market manipulation, although it is stated that this will not significantly impact the company's operations [15] - Sony raised its full-year operating profit forecast to 1.54 trillion yen, up from a previous estimate of 1.43 trillion yen, following a strong performance in the third quarter [24] Group 5 - Volvo reported fourth-quarter revenue of 94.4 billion Swedish Krona, down from 112.1 billion Swedish Krona year-on-year, with operating profit also declining [25] - NIO projected an adjusted operating profit of between 700 million to 1.2 billion RMB for the fourth quarter of 2025, marking its first quarter of adjusted operating profit [26]

Core Insights - The company reported annual revenue of approximately RMB 700 million to 720 million for the period ending December 31, 2025, representing a year-on-year growth of about 13.7% to 17.0% [1] Group 1: Revenue Growth - The continuous revenue growth is primarily attributed to the strong performance of all three product lines in the neurointervention business and the expanding market share in the transcatheter aortic valve replacement (TAVR) market, driven by the successful launch of the high-end TaurusMax 3D adjustable TAVR system [1] - All three product lines in neurointervention recorded robust revenue growth, reflecting strong performance of their core products [1] - The vascular access products saw revenue growth due to the increasing sales of the high-performance DCwire microcatheter, leading to a rapid increase in market share [1] Group 2: Product Performance - The hemorrhagic products benefited from the successful launch of the YonFlow blood flow-directed stent, which drove revenue growth for that product line [1] - Revenue growth in the ischemic product segment was mainly due to increased sales of the Syphonet thrombectomy stent and Tethys AS thrombectomy catheter [1] - Despite a price reduction in balloon dilation catheters following the implementation of volume-based procurement in the second half of 2025, sales volume significantly increased, particularly for the Fastunnel delivery balloon dilation catheter, keeping overall revenue stable compared to 2024 [1] Group 3: TAVR Market Expansion - The commercialized TAVR product portfolio was adopted in approximately 130 new hospitals during the reporting period, covering over 780 hospitals as of December 31, 2025 [2] - A total of approximately 3,900 units were implanted during the reporting period, representing a year-on-year growth of 14.4%, significantly exceeding the overall market growth rate [2] - With the registration application for the TaurusTrio transcatheter aortic valve system approved by the National Medical Products Administration in December 2025, the company anticipates a full commercialization in the Chinese aortic regurgitation market [2]

Core Viewpoint - Peijia Medical expects revenue in 2025 to be approximately 7.0 to 7.2 billion yuan, representing a year-on-year growth of about 13.7% to 17.0% driven by strong performance across all three product lines in the neurointervention business and an expanding market share in the transcatheter aortic valve replacement (TAVR) sector, primarily due to the successful launch of the high-end TaurusMax 3D adjustable TAVR system [1] Group 1 - The expected revenue for 2025 is projected to be around 7.0 to 7.2 billion yuan [1] - The year-on-year growth rate is estimated to be between 13.7% and 17.0% [1] - The growth is attributed to strong performance in all three product lines of the neurointervention business [1] Group 2 - The market share in the TAVR sector is continuously expanding [1] - The expansion is mainly driven by the successful launch of the TaurusMax 3D adjustable TAVR system [1]

Core Insights - The company reported annual revenue of approximately RMB 700 million to 720 million for the period ending December 31, 2025, representing a year-on-year growth of about 13.7% to 17.0% [1] Group 1: Revenue Growth - The continuous revenue growth is primarily attributed to the strong performance of all three major product lines in the neurointervention business and the expanding market share in the transcatheter aortic valve replacement (TAVR) market, driven by the successful launch of the high-end TaurusMax® 3D adjustable TAVR system [1] - All three major product lines in neurointervention recorded robust revenue growth, reflecting strong performance of their core products [1] Group 2: Product Performance - The vascular access products saw revenue growth, benefiting from the increasing sales of the high-performance DCwire® microcatheter, which significantly enhanced market share [1] - The hemorrhagic product line experienced revenue growth due to the successful launch of the YonFlow® flow-directed mesh stent [1] - The ischemic product line's revenue growth was mainly driven by increased sales of the Syphonet® thrombectomy stent and Tethys AS® thrombectomy catheter [1] Group 3: TAVR Market Expansion - The commercialized TAVR product portfolio was adopted in approximately 130 new hospitals during the reporting period, covering over 780 hospitals as of December 31, 2025 [2] - A total of approximately 3,900 units were implanted during the reporting period, representing a year-on-year growth of 14.4%, significantly exceeding the overall market growth rate [2] - The company anticipates full commercialization in the Chinese aortic regurgitation market following the approval of the registration application for the TaurusTrio® transcatheter aortic valve system by the National Medical Products Administration in December 2025 [2]

Core Viewpoint - The company, Peijia Medical-B (09996.HK), anticipates a revenue of approximately RMB 700 million to RMB 720 million for the fiscal year ending December 31, 2025, representing a year-on-year growth of about 13.7% to 17.0% compared to RMB 615.5 million in 2024, driven by strong performance across its neurointerventional product lines and an expanding market share in the TAVR segment [1]. Group 1: Revenue Growth Drivers - The neurointerventional business has shown robust revenue growth across all three product lines, reflecting strong performance of core products [2]. - Revenue growth in vascular access products is primarily attributed to the increasing sales of the high-performance DCwire® microcatheter, which has significantly enhanced market share [2]. - The hemorrhagic products segment has benefited from the successful launch of the YonFlow® flow-directed stent, contributing to revenue growth in this product line [2]. - Revenue growth in ischemic products is mainly due to increased sales of the Syphonet® thrombectomy stent and Tethys AS® thrombectomy catheter, with overall revenue stability despite price reductions following the implementation of volume-based procurement [2]. Group 2: TAVR Market Expansion - The company's commercialized TAVR product portfolio, including TaurusOne®, TaurusElite®, and TaurusMax® systems, has been adopted by approximately 130 new hospitals, reaching a total of over 780 hospitals by December 31, 2025 [2]. - A total of approximately 3,900 TAVR procedures were implanted during the reporting period, marking a year-on-year growth of 14.4%, significantly outpacing the overall market growth rate [3]. - The company expects to fully commercialize the TaurusTrio® transcatheter aortic valve system in the Chinese aortic regurgitation market following its approval by the National Medical Products Administration in December 2025 [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Peijia Medical Limited 沛嘉醫療有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股 份 代 號：9996） 自願性公告 截至2025年12月31日止年度的未經審核營運數據 本公告由沛嘉醫療有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 刊發，以向本公司股東及潛在投資者提供有關本集團最新業務及產品開發進 展的最新資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈本集團截至2025年12月31日止年度 （「報告期間」）的若干未經審核營運數據及比較數據載列如下。 1月1日至12月31日期間 | 2025年 | 2024年 | 變動 | | --- | --- | --- | | 人民幣百萬元 | 人民幣百萬元 | % | – 1 – 神經介入所有三大產品線均錄得穩健的收入增長，反映其各自核心產品的強 勁表現。主要驅動因素概述如下： 於報告期間，本 ...